Last reviewed · How we verify
Depo-Medrol
Depo-Medrol is a corticosteroid that suppresses the immune system and reduces inflammation by inhibiting the production and release of inflammatory mediators.
Depo-Medrol is a corticosteroid that suppresses the immune system and reduces inflammation by inhibiting the production and release of inflammatory mediators. Used for Rheumatoid arthritis and other inflammatory joint diseases, Allergic reactions and allergic dermatitis, Asthma and chronic obstructive pulmonary disease exacerbations.
At a glance
| Generic name | Depo-Medrol |
|---|---|
| Also known as | methylprednisolone |
| Sponsor | Hamilton Health Sciences Corporation |
| Drug class | Corticosteroid (glucocorticoid) |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology / Rheumatology / General anti-inflammatory |
| Phase | FDA-approved |
Mechanism of action
Methylprednisolone acetate, the active ingredient in Depo-Medrol, is a synthetic glucocorticoid that binds to intracellular glucocorticoid receptors, leading to decreased production of pro-inflammatory cytokines, chemokines, and adhesion molecules. This results in broad immunosuppression and anti-inflammatory effects. The depot formulation provides sustained release for prolonged therapeutic action.
Approved indications
- Rheumatoid arthritis and other inflammatory joint diseases
- Allergic reactions and allergic dermatitis
- Asthma and chronic obstructive pulmonary disease exacerbations
- Inflammatory bowel disease
- Systemic lupus erythematosus and other autoimmune conditions
- Adrenocortical insufficiency
Common side effects
- Hyperglycemia / elevated blood glucose
- Insomnia and mood changes
- Increased appetite and weight gain
- Hypertension
- Osteoporosis (with chronic use)
- Immunosuppression / increased infection risk
- Adrenal suppression
Key clinical trials
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- Pulse Glucocorticoid Therapy in Patients With ST-Segment Elevation Myocardial Infarction (PHASE2)
- Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma (PHASE3)
- Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia (PHASE2)
- MAGIC Ruxolitinib for aGVHD (PHASE2)
- Prehospital Pulse-dose Glucocorticoid in Patients With ST-segment Elevation Myocardial Infarction 2 - The PULSE-MI 2 Trial (PHASE3)
- Post-operative Methylprednisolone Taper Course for Orthopedic Surgery (PHASE4)
- TReatment for ImmUne Mediated PathopHysiology (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Depo-Medrol CI brief — competitive landscape report
- Depo-Medrol updates RSS · CI watch RSS
- Hamilton Health Sciences Corporation portfolio CI